Peter Kim, MD, Associate Professor, Department of Cardiology, Division of Internal Medicine at MD Anderson Cancer Center. In this video, he speaks about Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.
Abstract:
Immune checkpoint inhibitors (ICIs) have been shown to enhance outcomes in a variety of malignancies, and studies are being conducted to increase their indications and use. Immune-related adverse effects, such as myocarditis, have been identified, with myocarditis being linked to a high mortality rate. Arrhythmias, pericardial illness, and coronary atherosclerosis have all been reported in patients receiving ICI therapy. Increased inflammatory responses after the inactivation of particular checkpoint proteins on T cells are likely to be the cause of this cardiac toxicity. Although immunotherapy-related cardiotoxicity is said to be uncommon, it can be severe and lead to life-threatening situations such as fulminant myocarditis, hemodynamic instability, and cardiac arrest. We
‘ll go through the most frequent cardiovascular side effects linked with ICIs, as well as how to deal with them.